Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis).
Luigi GargiuloLuciano IbbaRuggero Cascio IngurgioPiergiorgio MalagoliFabrizio AmorusoAnna BalatoFederico BardazziPina BriantiGiovanna BrunassoMartina BurlandoAnna E CagniMarzia CaproniCarlo G CarreraAndrea CarugnoFrancesco CaudulloAldo CucciaPaolo DapavoEugenia V Di BrizziValentina DiniFrancesca M GaianiPaolo GisondiClaudio GuarneriClaudia LasagniGaetano LicataFrancesco LoconsoleAngelo V MarzanoMatteo MegnaSanto R MercuriMaria L MusumeciDiego OrsiniSimone RiberoValentina Ruffo Di CalabriaFrancesca SatolliDavide StrippoliMassimo TravagliniEmanuele TrovatoMarina VenturiniLeonardo ZichichiMario ValentiAntonio CostanzoAlessandra NarcisiPublished in: The Journal of dermatological treatment (2024)
Our data suggest that tildrakizumab 200 mg has better effectiveness than tildrakizumab 100 mg in patients with a body weight ≥ 90 kg and a high disease burden.